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ABSTRACT	
Purpose	
To	analyse	the	long-term	visual	acuity,	strabismus	and	nystagmus	outcomes	in	Group	D	
retinoblastoma	following	multimodality	treatments	in	a	national	retinoblastoma	referral	
centre.		
Design	
Retrospective	interventional	case	series.		
Methods	
A	13-year	retrospective	chart	review	of	Group	D	eyes	treated	initially	with	intravenous	
chemotherapy	(IVC)	and	followed-up	for	at	least	1	year	from	last	treatment.	Risk	factors	
for	final	visual	acuity	(VA)	were	analysed,	and	rate	of	strabismus	and	nystagmus	at	last	
follow-up	visit	were	calculated.		
Results	
One	hundred	and	four	Group	D	eyes	(92	patients)	presented	to	our	centre	during	the	
study	period,	of	which	32	(27	patients)	met	the	inclusion	criteria.	Following	IVC	
(vincristine,	etoposide	and	carboplatin),	adjuvant	treatments	included	intra-ophthalmic	
artery	chemotherapy	in	5	(16%)	eyes,	plaque	brachytherapy	in	5	(16%),	transpupillary	
thermotherapy	(TTT)	in	18	(56%)	and	cryotherapy	in	24	(75%)	eyes.	On	last	examination,	
64.41	±	6.76	months	from	presentation,	mean	final	VA	was	20/283	(logMAR	equivalent	of	
1.15±0.15).	On	univariate	analysis,	presentation	age,	foveal	retinoblastoma	(at	initial	
examination),	use	of	TTT	and	tumour-foveola	distance	(at	last	visit)	were	found	to	be	
significant	risk	factors	for	worse	VA	(p<0.026).	On	multivariate	analysis,	however,	only	TTT	
was	found	to	be	significant	(p=0.010).	At	last	visit,	6/27	(22%)	patients	had	nystagmus	and	
12/20	(60%)	of	bilaterally	salvaged	patients	had	strabismus	(n=10	exotropia	and	n=2	
esotropia).		
Conclusions		
Following	multimodality	treatments	initiated	with	IVC,	50%	of	salvaged	Group	D	
retinoblastoma	eyes	had	<20/200	vision,	with	TTT	being	a	risk	factor	for	worse	vision,	60%	
had	strabismus	and	22%	nystagmus.		
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INTRODUCTION	
Retinoblastoma	management	has	undergone	dramatic	changes	in	the	last	50	years,	
resulting	in	high	survival	rates,	estimated	at	98%	in	developed	countries,1	and	high	globe	
salvage	rates,	stratified	according	to	grade	of	tumour	burden.2	Intravenous	chemotherapy	
(IVC),	first	introduced	in	the	1990’s,3–6	was	found	to	achieve	>90%	tumour	control	when	
used	for	International	Intraocular	Retinoblastoma	Classification	(IIRC)7	groups	A-C,	and	47%	
in	cases	of	group	D	eyes.2	We	have	recently	reported	on	63%	group	D	eye	salvage	rate	using	
primary	IVC,	followed	by	adjuvant	modalities	as	required.8	Abramson	et	al.	reported	higher	
tumour	control	rates	using	primary	intra-ophthalmic	artery	chemotherapy	(IAC)	for	group	D	
eyes.9	Altogether,	most	D	eyes	today	are	successfully	managed	by	conservative	measures.	
Following	globe	salvage,	the	main	concern	focuses	on	functional	outcomes,	especially	visual	
acuity.10–15	There	is	only	scant	literature,	however,	on	long-term	visual	outcomes	of	
salvaged	IIRC	group	D	eyes,10,14,16	and	only	a	single	report	that	focused	purely	on	D	eyes.10		
Visually	deprived	children,	as	is	the	case	with	many	retinoblastoma	patients	with	a	foveal	
tumour	or	detached	fovea,	are	at	risk	of	developing	strabismus	and/or	nystagmus.	Both	
conditions	may	result	with	negative	psychosocial	implications	on	the	subjects’	life.17,18	At	
presentation,	leucocoria	is	a	more	common	feature	than	strabismus	and	far	more	common	
than	nystagmus.19	However,	strabismus	and	nystagmus,	may	persist,	worsen	or	develop	at	a	
later	stage	in	retinoblastoma	patients,	features	that	are	not	covered	in	the	retinoblastoma	
literature.		
The	goals	of	the	present	study	were	to	report	on	the	long-term	visual	and	orthoptic	
outcomes	in	salvaged	group	D	eyes	following	multimodality	treatments,	initiated	by	IVC.	The	
specific	aims	were	to	evaluate	the	long-term	visual	outcomes	in	this	population,	to	identify	
risk	factors	predictive	of	worse	visual	acuity	(VA),	and	to	report	on	the	rate	of	nystagmus	
and	strabismus	present	at	last	visit	in	this	population.		
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METHODS	
This	was	a	retrospective	chart	review	of	consecutive	IIRC	group	D	cases7	that	presented	to	
the	London	Retinoblastoma	Service	from	2002-2014	and	were	managed	initially	with	IVC.	
Only	salvaged	eyes	followed-up	for	12	months	or	more	from	last	treatment	were	included	
for	analysis.	The	study	was	approved	by	the	Barts	Health	NHS	Trust	institutional	review	
board	(number	6622),	which	waived	the	need	to	obtain	informed	consent	from	patients,	
and	was	executed	in	adherence	to	the	Declaration	of	Helsinki.		
Data	retrieved	from	clinical	notes	included	patients’	age,	gender,	family	history	of	
retinoblastoma,	clinical	variables	at	presentation	and	throughout	follow-up,	genetic	analysis	
results,	treatment	modalities,	and	orthoptic	evaluation.	All	RetCam	(Clarity	Medical	
Systems,	Pleasanton,	CA,	USA)	images,	as	well	as	fluorescein	angiograms	for	selected	
patients,	at	presentation	and	throughout	follow-up,	were	reviewed	and	analysed.	Fundus	
images	at	last	follow-up	visit	(RetCam	or	fundus	camera)	were	analysed	with	respect	to	
distance	(mm)	of	the	nearest	retinal	tumour	to	the	optic	disc	and	foveola,	choroidal	
ischaemia	at	the	macula/extra-macular	region,	retinal	pigment	(RP)	changes	at	the	
macula/extra-macular	region,	retinopathy	(i.e.	papillopathy,	maculopathy	and/or	elsewhere	
at	the	retina),	presence	of	retinal	detachment	at	the	macula/extra-macular	region	and	
tumour	regression	type.20,21	Macular	complications	were	recorded	only	in	cases	of	tumours	
≥1mm	from	the	foveola.		
IVC	(vincristine,	etoposide	and	carboplatin)	was	given	via	a	central	line,	approximately	once	
every	3	weeks,	for	6	cycles.	Focal	treatments,	given	for	tumour	relapse,	included	
cryotherapy,	transpupillary	thermotherapy	(TTT)	and	ruthenium	plaque	brachytherapy.	For	
cryotherapy,	a	cryosurgical	system	(Mira,	Waltham,	MA,	USA)	was	used,	and	each	treatment	
session	included	3x	freeze-thaw	cycles,	and	for	TTT	(Iris	Medical	OcuLight	SLx,	Iridex	
Corporation,	Mountain	View,	CA,	USA),	an	810nm	indirect	large	laser	spot	beam	was	used.	
In	cases	of	subfoveolar	tumours,	care	was	taken	to	spare	the	fovea	during	adjuvant	
treatment	with	TTT.	IAC	as	adjuvant/salvage	treatment	was	performed	as	described	
previously,22	using	melphalan	and/or	topotecan.	Intra-vitreous	chemotherapy	(IViC)	was	
first	used	in	our	service	in	2014,	hence	none	of	the	patients	in	the	present	cohort	received	
this	treatment.		
Orthoptic	evaluation	at	last	visit	included	cover	testing	at	near	(1/3	m)	and	distance	(6	m),	
ocular	motility	examination,	nystagmus	assessment	and	VA	examination.	Visual	acuity	was	
assessed	using	Cardiff	acuity	cards,	Kays	picture	tests,	Sheridan	Gardiner	Single	letters,	
Sheridan	Gardiner	Linear	letters,	or	Snellen	acuity,	depending	upon	the	age	of	the	child.	
Patients	in	whom	a	2	line	difference	was	found	between	eyes,	after	correction	of	refractive	
errors,	were	instructed	for	2-4	hours/day	patching	treatment	for	amblyopia.		
Statistical	analysis	
term	Orthoptic	Outcomes	in	Group	D	Retinoblastoma-gnLo	/et	al.		Fabian	
	
All	calculations	were	performed	using	Microsoft	Excel	2013	software	(Microsoft	
Corporation,	Redmond,	WA,	USA)	and	SPSS	software	version	17.0	(SPSS,	Inc.,	Chicago,	IL,	
USA).	Snellen	VA	was	converted	to	logMAR	equivalent.	Approximations	for	VA	worse	than	
20/400	were	as	follows:	counting	fingers,	20/2000;	hand	motions,	20/4000;	light	
perception,	20/8000;	and	no	light	perception,	20/16000.23	Clinical	correlations	to	final	VA	(a	
continuous	variable)	and	to	final	VA	worse	than	20/200	(a	categorical	variable)	were	
analyzed	using	Chi-square	or	Fisher's	Exact	Test	for	categorical	variables	and	T-Test	for	
continuous	ones.	Variables	found	significant	(P≤0.05)	on	univariate	analysis	were	further	
evaluated	using	multivariate	analysis	(Stepwise	Linear	Regression).	Results	throughout	the	
manuscript	are	presented	as	mean	±	standard	error	of	the	mean.		
	 	
term	Orthoptic	Outcomes	in	Group	D	Retinoblastoma-gnLo	/et	al.		Fabian	
	
RESULTS	
During	the	study	period,	104	group	D	eyes	of	92	patients	presented	and	were	treated	in	the	
London	Retinoblastoma	service.	Of	these,	40	eyes	(of	40	patients)	underwent	primary	
enucleation	and	the	remaining	64	(52	patients)	eyes	were	treated	initially	with	IVC.	Of	the	
64	eyes,	24	had	secondary	enucleation	and	40	were	salvaged.	Of	the	40	eyes,	32	(27	
patients)	were	followed-up	for	more	than	12	months	from	last	treatment	and	these	
comprise	the	study	group	(Figure	1).	In	terms	of	the	8th	edition	AJCC/UICC	clinical	staging	
system,24	included	were	1	(3%)	eye	classified	as	cT2aN0M0H0,	5	(16%)	as	cT2aN0M0H1,	6	
(19%)	as	cT2bN0M0H0	and	20	(63%)	as	cT2bN0M0H1.			
Table	1	summarizes	the	main	demographic	and	clinical	features	of	the	study	group.	Of	the	
27	study	patients,	9/27	(33%)	presented	with	unilateral	retinoblastoma,	and	the	remaining	
18/27	(67%)	with	bilateral	disease.	Of	the	bilateral	cases,	9/18	(50%)	were	bilateral	IIRC	
group	D	retinoblastoma	(in	3	of	these	cases	one	D	eye	was	enucleated	and	in	one	case,	
followed-up	for	less	than	12	moths,	hence	these	4	eyes	were	not	included	for	analysis),	and	
the	remaining	were	IIRC	groups	A	(n=2),	B	(n=1),	C	(n=3)	and	E	(n=3).	Modes	of	presentation	
included	leucocoria	in	15/27	(56%),	strabismus	in	8/27	(30%),	both	leucocoria	and	
strabismus	in	3/27	(11%),	and	in	a	single	(4%)	patient	the	presenting	sign	was	nystagmus.	
The	age	of	presentation	was	12.41	±	9.90	months.	There	were	25/32	(78%)	cases	that	had	
RB1	mutation	and	7/32	(22%)	which	also	had	a	family	history	of	retinoblastoma.	Findings	at	
first	clinical	examinations	included	retinoblastoma	occupying	the	fovea	in	23/32	(72%)	
cases,	subretinal	seeds	in	17/32	(53%),	vitreous	seeds	in	14/32	(44%)	and	a	detached	retina	
in	26/32	(81%)	cases.	Adjuvant	treatments	given	after	IVC	included	IAC	in	5/32	(16%)	cases	
(mean	number	of	treatments:	3±1),	plaque	brachytherapy	in	5/32	(16%)	cases,	TTT	in	18/32	
(56%)	cases	(mean	number	of	applications:	2±0.5)	and	cryotherapy	in	24/32	(75%)	cases	
(mean	number	of	applications:	3±0.8).	External	beam	radiation	(EBRT)	was	not	used	in	any	
of	the	patients.		
At	last	visit,	tumour	regression	types	were	type	I	in	17/32	(53%)	cases,	type	III	in	14/32	
(44%)	and	type	IV	in	a	single	(3%)	case,	and	tumour	distances	from	the	foveola	and	optic	
disc	were	1.94	±	0.52mm	and	2.00	±	0.44mm,	respectively.	Altogether,	in	12/32	(37%)	cases,	
tumours	were	located	≥1mm	from	the	foveola.	Choroidal	ischaemia	was	present	at	the	
macula	in	1/12	(8%)	case	and	in	the	extra-macular	region	in	5/32	(16%)	cases,	4	of	which	
had	previous	IAC.	Macular	retinal	pigment	epithelial	changes	were	present	in	8/12	(67%)	
cases	and	extra-macular	RP	changes	in	28/32	(88%)	cases.	Extra-macular	radiation	
retinopathy	was	present	in	5/32	(16%)	cases,	all	of	which	previously	had	plaque	
brachytherapy.	A	detached	macula	was	present	in	1/12	(8%)	case,	a	partially	detached	
retina	in	3/32	(9%)	cases	and	a	total	retinal	detachment	in	1/32	(3%).	Of	the	12	cases	in	
which	the	tumour	was	≥1mm	of	the	foveola,	9/12	(75%)	showed	one	of	these	of	macular	
abnormalities.		
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The	mean	final	VA	was	20/283	(logMAR	vision	equivalent	of	1.15±0.15)	but	7	(22%)	cases	
had	VA	of	20/40	or	better,	and	16	(50%),	VA	of	20/200	or	better.	The	total	mean	follow-up	
time	was	64.41	±	6.76	months	and	the	interval	from	last	treatment	to	last	visit	was	50.70	±	
7.08	months.	On	univariate	analysis,	variables	at	presentation	that	correlated	with	
decreased	final	VA	included	young	age	of	presentation	(P=0.017)	and	foveal	retinoblastoma	
(P=0.002).	Additional	significant	variables	were	TTT	(P=0.026)	and	distance	of	tumour	to	
foveola	at	last	visit	(P=0.003).	Table	1	shows	the	univariate	and	Table	2	the	multivariate	
analysis	results	of	the	clinical	correlations	to	decreased	final	VA.	On	multivariate	analysis,	
the	only	significant	variable	found	was	TTT	(P=0.010).	Similar	clinical	variables	were	found	to	
correlate	on	univariate	analysis	to	final	VA	of	20/200	or	worse,	while	TTT	was	the	only	
predictor	found	on	multivariate	analysis	(P=0.029).		
Orthoptic	evaluations	to	examine	strabismus	and	nystagmus	at	the	end	of	the	study	period	
are	shown	in	Table	3.	At	last	follow-up	visit,	7/27	(26%)	patients	had	one	eye	removed	(1	
group	C,	3	group	D	and	3	group	E).	Of	the	20/27	(74%)	remaining	patients,	a	form	of	
strabismus	(i.e.	true,	alternate	or	intermittent	squint)	was	present	in	15/20	(75%)	of	
patients.	Of	these,	true	exotropia	was	the	predominant	form,	present	in	10/15	(67%)	
patients,	and	true	esotropia	in	2/15	(13%)	patients.	There	were	2/20	(10%)	patients	that	had	
in	addition	to	the	horizontal	squint	also	a	vertical	component.	None	of	the	patients	reported	
diplopia.	Of	note,	at	study	closure,	none	of	the	patients	had	received	strabismus	surgery	or	
botulinum	toxin	injections	and	none	had	developed	cataract.		
At	last	visit,	6/27	(22%)	patients	had	nystagmus.	Their	mean	age	of	presentation	with	
retinoblastoma	was	7.6±2.4	months.	In	all	cases,	patients	had	bilateral	advanced	(≥IIRC	
Group	D	or	cT2N0M0)	retinoblastoma,	involving	the	fovea.	Three	patients	(50%)	had	one	
eye	enucleated	(D	eye	remained)	and	in	3/6	(50%)	had	bilateral	salvaged	group	D	eyes.	
None	of	the	patients	had	a	pinealblastoma	or	other	brain	tumour.	During	the	study	period,	
none	of	the	patients	developed	metastasis	and	all	were	alive.		
	
	
	
	 	
term	Orthoptic	Outcomes	in	Group	D	Retinoblastoma-gnLo	/et	al.		Fabian	
	
DISCUSSION	
Until	recently,	attempts	to	salvage	IIRC	group	D	eyes	resulted	with	less	than	50%	success	
rate.2	With	the	recent	advent	of	IAC	and	IViC,	salvage	rates	have	increased	considerably	to	
reach	>60%	with	first-line	IVC	and	subsequent	IAC	as	salvage,8	and	>80%	when	IAC	was	used	
as	the	primary	treatment	modality.9	Initial	attention	is	focused	on	controlling	the	disease,	
but	once	the	child	survives	the	cancer,	there	is	usually	some	degree	of	ocular	morbidity,	that	
may	affect	quality	of	life.	In	the	chemotherapy	era,	survivors	of	retinoblastoma	(and	their	
parents)	are	often	concerned	about	visual	acuity	and	residual	squint.	In	this	study	we	have	
attempted	to	evaluate	our	results	from	visual	and	orthoptic	testing	exclusively	in	Group	D	
eyes	at	a	mean	follow-up	of	over	5	years,	so	that	retinoblastoma	specialists	can	more	
accurately	counsel	families.	Our	results	have	shown	that	nearly	50%	of	Group	D	eyes	had	VA	
of	<20/200	and	75%	had	some	form	of	strabismus.		
There	is	little	reported	on	visual	outcomes	of	salvaged	group	D	eyes	following	
chemotherapy.10,14,16	Batra	et	al.	evaluated	vision	in	45	eyes	classified	as	IIRC	A-D,	
subgrouping	them	to	A+B	and	C+D	(n=27	eyes).14	More	than	half	of	eyes	in	the	latter	
subgroup	had	final	VA	of	20/40	or	worse.	No	sub-analysis,	however,	was	performed	on	D	
eyes.	In	that	report,	IIRC	groups	C+D	patients	were	found	to	be	at	a	higher	risk	of	poor	
vision.	Narang	et	al.	determined	the	predictors	of	long-term	visual	outcomes	after	
chemoreduction,	including	all	IIRC	groups,	even	Group	E	eyes.16	In	their	cohort	there	were	
22	group	D	eyes,	91%	of	which	reached	a	final	VA	worse	than	20/40.	IIRC	group	was	found	
to	be	a	significant	predictor	for	poor	vision,	among	other	factors,	but	on	multivariate	
analysis	only	tumour	distance	to	the	fovea	and	number	of	tumours	were	found	to	play	a	
role.	There	was	no	group	D	sub-analysis	in	that	study.	Berry	et	al.	evaluated	the	outcomes	of	
group	D	eyes	of	bilateral	retinoblastoma	patients	treated	with	primary	chemoreduction	and	
EBRT	(In	the	form	of	low-dose	intensity	modulated	radiation	therapy)	as	salvage.10	
Altogether,	45	eyes	were	salvaged,	24	of	which	were	also	treated	with	EBRT.	However,	
logMAR	vision	was	available	only	for	25	eyes;	in	20	eyes	visual	acuity	assessment	was	of	fix	
and	follow	only,	due	to	patients’	age.	In	addition,	some	of	the	patients	were	followed-up	for	
a	relatively	short	period	of	less	than	one	year.	Of	note,	all	of	these	studies	were	before	the	
widespread	introduction	of	IAC.		
According	to	the	present	study	salvaged	group	D	eyes	are	equally	likely	to	have	vision	worse	
than	20/200	(ambulatory	vision).	Younger	patients,	those	with	foveal	tumours	(as	estimated	
on	first	examination	or	measured	on	last	examination)	and	especially	those	treated	with	TTT	
were	found	to	be	at	higher	risk	to	have	worse	final	vision.	The	main	goal	in	treating	
retinoblastoma	is	to	reach	tumour	control,	to	avoid	metastatic	spread	and	to	save	the	globe,	
even	at	the	risk	of	scarifying	vision.	TTT	is	a	very	efficient	modality	for	posterior	pole	
retinoblastoma,	used	as	adjuvant	to	first-line	chemotherapy	as	well	as	for	tumour	relapse,	
as	is	the	indication	in	our	service.	As	adjunct	therapy,	there	is	no	consensus	regarding	the	
recommended	timing	of	use	–	in	every	case	in	conjunction	with	chemotherapy,	or	as	
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required	according	to	the	response	to	chemotherapy.5,25,26	Either	way,	as	a	focal	treatment	
it	is	commonly	used	in	eyes	treated	with	systemic	chemotherapy,27	as	well	as	in	eyes	
treated	with	IAC.9	Interestingly,	Schefler	at	al.	investigated	the	impact	of	systemic	
chemotherapy	and	TTT	on	macular	retinoblastoma	(Reese-Ellsworth	groups	I-V)	in	respect	
to	visual	functions	and	found	that	11/14	(79%)	had	VA≥20/200	at	final	visit.28	These	
excellent	results,	however,	were	not	repeated	in	the	present	study.		
Visual	deprivation	may	result	in	strabismus,	nystagmus	and	amblyopia,	and	in	this	cohort	in	
63%	of	eyes	tumours	were	located	<1mm	from	the	fovea,	and	of	the	remaining	eyes,	75%	
had	macular	abnormality	associated	with	an	adjacent	tumour,	detached	retina	and/or	
treatment	side	effects.	Infantile	nystagmus	may	further	limit	visual	acuity	due	to	the	ocular	
oscillations	and	inability	to	maintain	stable	foveal	fixation.29	it	was	reported	to	develop	in	
association	with	several	ocular	abnormalities,	including	foveal	hypoplasia,	optic	nerve	
hypoplasia/dysplasia,	optic	atrophy,	retinopathies	and	congenital	cataract,30	but	to	the	best	
of	our	knowledge	was	not	previously	reported	in	association	with	retinoblastoma.	
Strabismus	in	this	population	could	theoretically	also	be	a	result	of	extraocular	muscle	palsy	
after	IAC.31	However,	this	complication	was	not	noted	in	the	5	study	patients	who	received	
this	treatment.	Strabismus	and	nystagmus	are	known	to	be	associated	with	psychosocial	
difficulties	and	have	an	overall	adverse	impact	on	patients’	quality	of	life.17,18,32	Strabismus	
was	also	found	to	adversely	influence	observers.33	Interestingly,	none	of	the	children	in	the	
present	cohort	had	squint	surgery,	some	of	whom	were	in	their	teenage	years.	Secondary	
sensory	strabismus	cases	may	benefit	from	eye	muscle	surgery,	although	this	was	not	
evaluated	in	retinoblastoma	patients.34	Having	had	multiple	treatments	for	globe	salvage	
under	general	anaesthesia	in	young	age,	it	is	possible	that	patients	and	families	find	surgical	
strabismus	correction	unappealing	in	later	life.			
The	main	limitation	of	this	study	is	its	retrospective	design.	For	visual	outcome	analysis	all	
clinical	variables	were	available,	and	we	could	calculate	risk	factors	for	poor	final	vision.	
However,	for	strabismus	and	nystagmus,	it	was	the	final	rates	that	were	assessed.	The	
presence	of	squint	was	always	noted	in	the	medical	history,	but	an	accurate	orthoptic	
measurement	at	presentation	was	not	always	possible.	Despite	these	constraints,	this	study	
is	currently	the	largest	to	report	on	group	D	eyes’	visual	outcomes	after	multimodality	
treatments.	To	the	best	of	our	knowledge,	it	is	also	the	first	study	to	report	on	the	rate	of	
strabismus	and	nystagmus	at	last	visit.	As	treatments	evolve	with	wider	use	of	IAC	and	
intravitreal	chemotherapy	injections,	it	will	be	interesting	to	evaluate	the	long	term	visual	
and	orthoptic	examination	with	these	new	treatments	and	hence	the	current	report	will	
serve	as	a	baseline	for	the	era	of	systemic	chemotherapy.		
In	summary,	following	multimodality	treatments	for	group	D	retinoblastoma	patients	and	
mean	follow-up	time	of	64	months,	final	mean	visual	acuity	was	20/283.	Depending	on	age	
of	presentation,	tumour	location	in	respect	to	the	foveola	and	mainly	whether	adjuvant	TTT	
was	applied,	final	VA	was	better/worse	than	20/200.	At	last	visit,	60%	of	patients	had	
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exotropia	or	esotropia	and	22%	had	nystagmus.	With	the	expectation	of	improved	salvage	
rates	for	group	D	eyes,	these	results	are	useful	information	for	clinicians,	patients	and	
patients’	families.		 	
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FIGURE	LEGEND	
Figure	1	-	Modified	CONSORT	(Consolidated	Standards	of	Reporting	Trials)	Diagram	showing	
the	progress	of	patients	through	the	study.	
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Table	1.	Correlations	to	final	logMAR	vision	equivalent	in	salvaged	group	D	retinoblastoma	
eyes:	univariate	analysis	
Parameter		 Number	(%)/mean	±	
std.	error	mean	
Mean	logMAR	±	std.	
error	mean	
Significance	
Demographics	and	genetics	 	 	 	
Gender	
										Male	
										Female	
	
14	(44)	
18	(56)	
	
1.36	±	0.21	
0.99	±	0.20	
0.211	
Age	of	presentation	(months)	 12.41	±	1.75	 NA	 0.017	
Family	history	of	Rb	
										Sporadic	
										Familial	
	
25	(78)	
7	(22)	
	
1.18	±	0.16	
1.07	±	0.40	
0.770	
Germline	disease	
										Genetic	
										Non-genetic	
	
25	(78)	
7	(22)	
	
1.19	±	0.17	
1.04	±	0.33	
0.679	
First	clinical	examination	 	 	 	
Laterality	
										Right	eye	
										Left	eye	
	
16	(50)	
16	(50)	
	
1.26	±	0.22	
1.04	±	0.19	
0.464	
Tumour	elevation	(mm)	 9.16	±	0.49	 NA	 0.337	
Tumour	base	(mm)	 11.43	±	0.57	 NA	 0.982	
Retinal	detachment		
										Yes	
										No	
	
26	(81)	
6	(19)	
	
1.11	±	0.15	
1.37	±	0.44	
0.495	
Foveal	Rb	
										Yes	
										No	
	
23	(72)	
9	(28)	
	
1.42	±	0.15	
0.47	±	0.22	
0.002	
Subretinal	seeds	
										Yes	
										No	
	
17	(53)	
15	(47)	
	
1.27	±	0.17	
1.03	±	0.25	
0.417	
Vitreous	seeds	
										Yes	
										No	
	
14	(44)	
18	(56)	
	
0.84	±	0.22	
1.40	±	0.18	
0.057	
Adjuvant	treatments	 	 	 	
IAC	
										Yes	
										No	
	
5	(16)	
27	(84)	
	
1.19	±	0.40	
1.15	±	0.16	
0.923	
Plaque	brachytherapy	
										Yes	
										No	
	
5	(19)	
27	(81)	
	
0.60	±	0.19	
1.26	±	0.16	
0.102	
TTT	
										Yes	
										No	
	
18	(56)	
14	(44)	
	
1.44	±	0.20	
0.79	±	0.18	
0.026	
Cryotherapy	
										Yes	
										No	
	
24	(75)	
8	(25)	
	
1.00	±	0.17	
1.61	±	0.26	
0.072	
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Last	visit	examination	and	
follow-up	
	 	 	
Tumour	–	foveola	at	last	visit	
(mm)	
1.94	±	0.52	 NA	 0.003	
Tumour	–	optic	disc	at	last	
visit	(mm)	
2.00	±	0.44	 NA	 0.369	
Follow-up	(months)	 64.41	±	6.76	 NA	 0.938	
Last	treatment	–	last	follow-
up	(months)	
50.70	±	7.08	 NA	 0.700	
Rb	–	retinoblastoma,	IAC	–	intra-ophthalmic	artery	chemotherapy,	TTT	–	transpupillary	
thermotherapy.	NA	–	not	applicable,	as	analysed	as	a	continuous	parameter.		
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Table	2.	Correlations	to	final	logMAR	vision	equivalent	in	salvaged	group	D	retinoblastoma	eyes:	
multivariate	analysis	(Stepwise	Linear	Regression).	
Parameter	 Unstandardized	
Coefficients	(β)	
95%	Confidence	
Interval	for	β	
Significance	
Age	of	presentation	(mm)	 -0.024	 (-0.053)-0.004	 0.093	
Foveal	Rb	(yes	vs.	no)	 0.363	 (-0.559)-1.285	 0.426	
TTT	(yes	vs.	no)	 0.664	 0.175-1.153	 0.010	
Tumour	–	fovea	at	last	visit	(mm)	 -0.055	 (-0.211)-0.101	 0.475	
Rb	–	retinoblastoma,	TTT	–	transpupillary	thermotherapy.		
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Table	3.	Visual	acuity,	strabismus	and	nystagmus	at	final	visit	in	32	(27	patients)	salvaged	group	D	eyes	following	multimodality	treatment.		
Patient#		 IIRC	
(R/L)	
cTNMH*	
(R/L)	
Age	of	presentation	
(months)	
Presenting	sign	 Final	
logMAR	R	
Final	
logMAR	L	
Nystagmus	 Strabismus	
1	 D/D	 cT2bN0M0H1/cT2bN0M0H1	 19.6	 Leukocoria	 0.9	 Enucleated	 Nil	 NA	
2	 D/D	 cT2bN0M0H1/cT2bN0M0H1	 4.4	 Leukocoria	 1	 1.1	 Yes	 Alt	ET	
3	 D/D	 cT2bN0M0H1/cT2bN0M0H1	 2.5	 Leukocoria	 2.3	 Enucleated	 Yes	 NA	
4	 B/D	 cT1bN0M0H1/cT2bN0M0H1	 14.8	 Strabismus	 0.08	 1.3	 Nil	 LXT,	LHoT,	LIO	u/a	
5	 E/D	 cT3cN0M0H1/cT2bN0M0H1	 9.9	 Strabismus	 Enucleated	 0.7	 Nil	 NA	
6	 D/D	 cT2bN0M0H1/cT2aN0M0H1	 23.7	 Strabismus	 0.3	 Enucleation	 Nil	 NA	
7	 D/D	 cT2bN0M0H1/cT2bN0M0H1	 4.6	 Leukocoria	 0.1	 -0.2	 Nil	 RX(T)	
8	 0/D	 cT0N0M0H0/cT2aN0M0H0	 1.6	 Leukocoria	 -0.06	 1.8	 Nil	 LXT	
9	 C/D	 cT2bN0M0H1/cT2aN0M0H1	 2.3	 Leukocoria	 0.1	 1.8	 Nil	 Nil	
10	 D/C	 cT2aN0M0H1/cT2bNoMoH1	 10.8	 Leukocoria	+	strabismus	 2.6	 0.02	 Nil	 Nil	
11	 D/E	 cT2bN0M0H1/cT3cN0M0H1	 17.7	 Leukocoria	+	strabismus	 0.88	 Enucleated	 Yes	 NA	
12	 D/D	 cT2bN0M0H1/cT2bN0M0H1	 5.9	 Leukocoria	 1.2	 1.2**	 Yes	 Alt	XT	
13	 0/D	 cT0N0M0H0/cT2bN0M0H0	 12.6	 Strabismus	 0.04	 1.12	 Nil	 LXT	
14	 0/D	 cT0N0M0H0/cT2bN0M0H0	 11.7	 Leukocoria	 0	 2.08	 Nil	 LXT	
15	 D/D	 cT2aN0M0H1/cT2aN0M0H1	 11.4	 Nystagmus	 1.3	 0.4	 Yes	 RXT	
16	 D/D	 cT2bN0M0H1/cT2bN0M0H1	 11.1	 Strabismus	 2.08	 0.5	 Nil	 RXT	
17	 E/D	 cT3bN0M0H1/cT2bN0M0H1	 3.6	 Leukocoria	 Enucleated	 1.38	 Yes	 NA	
18	 D/C	 cT2bN0M0H1/cT2bN0M0H1	 16.4	 Strabismus	 0.9	 Enucleated	 Nil	 NA	
19	 D/A	 cT2bN0M0H1/cT1aN0M0H1	 1.9	 Strabismus	 2.6	 0.1	 Nil	 RXT	
20	 0/D	 cT0N0M0H0/cT2bN0M0H0	 13.1	 Leukocoria	 0	 1.78	 Nil	 LXT	
21	 0/D	 cT0N0M0H0/cT2bN0M0H0	 7.3	 Leukocoria	 0	 0.26	 Nil	 Nil	
22	 D/D	 cT2bN0M0H1/cT2aN0M0H1	 19.3	 Leukocoria	 0.9	 0.16	 Nil	 RET	
23	 D/0	 cT2bN0M0H0/cT0N0M0H0	 50.4	 Leukocoria	 0.1	 0	 Nil	 Nil	
24	 D/0	 cT2bN0M0H1/cT0N0M0H1	 15.1	 Leukocoria	 0.62	 -0.02	 Nil	 Nil	
25	 D/A	 cT2bN0M0H1/cT1aN0M0H1	 9.5	 Leukocoria	 2.6	 0.2	 Nil	 RXT	
26	 0/D	 cT0N0M0H1/cT2bN0M0H1	 12.1	 Strabismus	 0	 2.3	 Nil	 LXT	
27	 D/0	 cT2bN0M0H0/cT0N0M0H0	 32.9	 Leukocoria	+	strabismus	 0.14	 -0.02	 Nil	 RET,	RSO	palsy,	RHT	
	–exotropia,	HoT		–esotropia,	XT		–alternate,	ET		–applicable,	Alt	-non	–left,	NA		–right,	L		–R		7International	Intraocular	Retinoblastoma	Classification,	–IIRC	
hypotropia,	IO	–	inferior	oblique,	u/a	–	under	action,	X(T)	–	intermittent	exotropia,	SO	–	superior	oblique,	HT	–	hypertropia.		
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24.staging	systemedition	AJCC/UICC	clinical		th8	*	
**	Less	than	12	months	of	follow-up	since	last	treatment,	hence	not	included	for	visual	outcomes	analysis.		
	
